AMRX vs ALVO vs RDY Stock Comparison

Amneal Pharmaceuticals, Alvotech and Dr Reddys Laboratories Prices as of Nov 13, 2026 Peers: Industry group
ALVO Alvotech
$4.19 -19.0% 1M -24.1% 1Y
Market cap
$1.27B
P/E
–
Revenue (TTM)
-$131.44M
Div. yield
–
Generic Drugs Healthcare

Head to Head

11 decided of 12

Amneal Pharmaceuticals leads on 6 of the 12 questions below (Amneal Pharmaceuticals 6, Dr Reddys Laboratories 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMRXALVORDYLeader
Larger companyMarket capitalisation $7.10B $1.27B $12.24B RDY
Cheaper on earningsLower P/E, profitable companies only 53.2x -41.2x 33.7x RDY
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.4x — 30.7x AMRX
Faster revenue growthRevenue growth, trailing twelve months +8.9% -137.5% -10.5% AMRX
More profitableNet margin, trailing twelve months 4.2% — 10.2% RDY
Better return on capitalReturn on invested capital 14.3% 8.2% 5.6% AMRX
Less leveragedLower net debt / EBITDA 4.3x 4.6x 1.2x RDY
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +85.6% -24.1% +6.3% AMRX
Better 5-year returnAnnualised price return, 5 years +32.7%/yr -15.8%/yr +2.5%/yr AMRX
Less volatileAnnualised volatility, 1 year 34.3% 70.5% 26.6% RDY
Higher overall scoreMean of the five percentile scores vs peers 69/100 66/100 57/100 AMRX

Percentile Scorecard

AMRXALVORDY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMRXALVORDY
Valuation 90 #69 of 660 94 #41 of 660 90 #66 of 660
Growth 70 #189 of 619 79 #132 of 619 12 #546 of 619
Profitability 87 #80 of 595 71 #172 of 595 85 #92 of 595
Financial Health 11 #606 of 683 22 #536 of 683 41 #405 of 683
Shareholder Returns 89 #53 of 459 – 60 #186 of 459
Overall 69 66 57
  • AMRX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • ALVO ranked among 695 companies in Pharmaceuticals and Biotechnology
  • RDY ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMRXALVORDYSPY
1 month +13.1%-19.0%+15.7% -2.0%
3 months +17.8%+3.5%+20.1% -2.8%
6 months +79.2%+26.6%+8.4% +2.0%
Year to date +69.7%-18.3%+5.1% +10.6%
1 year +85.6%-24.1%+6.3% +12.2%
3 years +367.8%-53.4%+13.0% +68.1%
3 years, per year +67.3%-22.5%+4.2% +18.9%
5 years +310.4%-57.7%+13.4% +61.4%
5 years, per year +32.7%-15.8%+2.5% +10.1%
10 years ——+52.0% +248.5%
10 years, per year ——+4.3% +13.3%

Risk

MeasureAMRXALVORDYSPY
Volatility, 1Y 34.3%70.5%26.6% 13.6%
Downside volatility, 1Y 30.7%65.0%27.6% 13.9%
Beta vs S&P 500, 1Y 0.670.840.34 1.00
Return / volatility, 1Y 2.49-0.340.24 0.90
Max drawdown, 5Y -75.4%-82.6%-32.3% -25.4%
From 52-week high -1.5%-31.9%-4.1% -3.2%
52-week high $21.71$6.15$15.38 $779.14
52-week low $11.52$3.00$11.40 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMRXALVORDY
P/E now vs peer median 53.8xmedian 17.0x -39.2xmedian 17.0x 33.8xmedian 17.0x
P/S now vs peer median 2.3xmedian 8.4x -9.9xmedian 8.4x 3.5xmedian 8.4x
EV/EBITDA now vs peer median 15.1xmedian 14.6x 9.5xmedian 14.6x 24.4xmedian 14.6x
P/FCF now vs peer median 193.9xmedian 19.0x -10.7xmedian 19.0x 882.1xmedian 19.0x
P/B now vs peer median 14.0xmedian 2.0x -4.6xmedian 2.0x 3.0xmedian 2.0x
PEG now vs peer median 0.65median 0.43 —median 0.43 -1.59median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMRXALVORDY
Revenue $3.20B -$131.44M $174.86B
Gross profit $1.29B -$270.71M $86.67B
Operating income $478.99M $142.52M $16.77B
Net income $175.49M $52.16M $275.07M
Free cash flow $38.42M -$122.64M $400.42M
R&D $180.59M $92.89M $12.52B
EPS (diluted) $0.40 $-0.11 $0.44
Cash & equivalents $157.40M $172.36M $138.41M
Total debt $3.12B $1.40B $783.69M
Shares (diluted) 335.73M 291.34M 833.33M
Enterprise value $6.33B $723.45M $11.58B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMRXALVORDY
P/E 53.8x -39.2x 33.8x
P/FCF 193.9x -10.7x 882.1x
P/Operating cash flow 41.2x -22.5x 36.2x
P/S 2.3x -9.9x 3.5x
P/B 14.0x -4.6x 3.0x
P/Tangible book -7.3x -2.8x 4.1x
EV/EBITDA 15.1x 9.5x 24.4x
EV/EBIT 21.7x 17.8x 37.2x
EV/Revenue 3.3x -19.3x 3.6x
EV/FCF 271.0x -20.6x 926.1x
EV/Operating cash flow 57.6x -43.5x 38.0x
PEG (3Y EPS CAGR) 0.65 – -1.59

Growth

14 metrics
MetricAMRXALVORDY
Revenue growth (1Y) 8.9% -137.5% -10.5%
Revenue CAGR (3Y) 10.2% – 3.2%
Gross profit growth (1Y) 19.2% -383.2% -21.5%
Gross profit CAGR (3Y) 15.0% – -2.3%
Operating income growth (1Y) 33.8% 166.0% -58.2%
Operating income CAGR (3Y) 28.4% – -24.1%
Net income growth (1Y) 271.2% 122.5% -55.9%
Net income CAGR (3Y) 53.6% – -21.5%
EPS growth (1Y) 2,085% 87.7% -54.1%
EPS CAGR (3Y) 83.1% – -21.3%
Operating cash flow growth (1Y) -44.9% 75.4% -39.6%
Operating cash flow CAGR (3Y) -1.1% – -27.1%
Free cash flow growth (1Y) -84.6% 52.6% -98.4%
Free cash flow CAGR (3Y) -35.0% – -73.6%

Profitability

14 metrics
MetricAMRXALVORDY
Gross margin 40.2% – 49.5%
EBITDA margin 21.5% – 14.9%
Operating margin 15.0% – 9.7%
Pretax margin 6.9% – 10.7%
Net margin 4.2% – 10.2%
FCF margin 1.2% – 0.4%
Operating cash flow margin 5.7% 44.3% 9.5%
Return on equity 74.3% – 7.4%
Return on assets 4.6% -1.9% 5.0%
Return on invested capital 14.3% 8.2% 5.6%
Return on capital employed 14.1% 11.0% 7.9%
Asset turnover 0.7x -0.1x 0.6x
Cash conversion (OCF / net income) 1.0x -1.1x 1.1x
Stock comp / revenue 1.2% -5.0% 0.1%

Financial Health

11 metrics
MetricAMRXALVORDY
Debt / assets 59.2% 86.4% 12.6%
Debt / equity 5.9x -4.9x 0.2x
Net debt / EBITDA 4.3x 4.6x 1.2x
Debt / FCF 81.2x -11.4x 53.9x
Liabilities / assets 89.9% 117.6% 32.2%
Equity / assets 10.1% -17.6% 67.8%
Interest coverage – 44.7x 7.2x
Current ratio 1.9x 1.9x 1.9x
Quick ratio 1.1x 1.4x 0.7x
Cash ratio 0.1x 0.6x 0.1x
Altman Z-score 1.96 -1.39 5.79

Shareholder Returns

7 metrics
MetricAMRXALVORDY
Dividend yield – – 0.5%
Net buyback yield 0.0% – -0.1%
Shareholder yield 0.0% – 0.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMRXALVORDY
Forward P/E 21.4xFY2026 – 30.7xFY2026
EPS, next fiscal year $1.00FY2026 $-0.04FY2026 $0.48FY2026
EPS growth, next FY +20.5%FY2026 – -11.1%FY2026
EPS growth, the year after +26.0% – +20.8%
Revenue, next fiscal year $3.30BFY2026 $555.88MFY2026 $3.84BFY2026
Revenue growth, next FY +9.1%FY2026 -6.3%FY2026 +9.3%FY2026
Revenue growth, the year after +12.6% +23.4% +3.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMRXALVORDY
Held by institutions 51.0% 14.7% 15.1%
Institutions holding 310 72 239
Change in shares held, QoQ +1.3% +152.4% +4.3%
Institutions buying 182 44 108
Institutions selling 86 17 97
Buyers to sellers 2.12 2.59 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMRXALVORDY
AMRX 1.00 0.19 0.24
ALVO 0.19 1.00 0.13
RDY 0.24 0.13 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMRX, ALVO and RDY?

Dr Reddys Laboratories (RDY) is the largest by market capitalisation: Amneal Pharmaceuticals (AMRX) $7.10B, Alvotech (ALVO) $1.27B, Dr Reddys Laboratories (RDY) $12.24B.

Which stock is cheaper, AMRX, ALVO and RDY?

Dr Reddys Laboratories (RDY) trades on the lowest price-to-earnings ratio (Amneal Pharmaceuticals (AMRX) 53.2x, Alvotech (ALVO) -41.2x, Dr Reddys Laboratories (RDY) 33.7x). On next year's consensus earnings, Amneal Pharmaceuticals (AMRX) is cheapest (Amneal Pharmaceuticals (AMRX) 21.4x, Dr Reddys Laboratories (RDY) 30.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Amneal Pharmaceuticals (AMRX) grew revenue fastest over the trailing twelve months: Amneal Pharmaceuticals (AMRX) +8.9%, Alvotech (ALVO) -137.5%, Dr Reddys Laboratories (RDY) -10.5%.

Which company is more profitable?

Dr Reddys Laboratories (RDY) has the highest net margin (Amneal Pharmaceuticals (AMRX) 4.2%, Dr Reddys Laboratories (RDY) 10.2%). On return on invested capital, Amneal Pharmaceuticals (AMRX) leads (Amneal Pharmaceuticals (AMRX) 14.3%, Alvotech (ALVO) 8.2%, Dr Reddys Laboratories (RDY) 5.6%).

Which stock has performed better?

Over the past year Amneal Pharmaceuticals (AMRX) returned the most: Amneal Pharmaceuticals (AMRX) +85.6%, Alvotech (ALVO) -24.1%, Dr Reddys Laboratories (RDY) +6.3%. Over five years, Amneal Pharmaceuticals (AMRX) compounded fastest (Amneal Pharmaceuticals (AMRX) +32.7%/yr, Alvotech (ALVO) -15.8%/yr, Dr Reddys Laboratories (RDY) +2.5%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Dr Reddys Laboratories (RDY) has been the steadiest (Amneal Pharmaceuticals (AMRX) 34.3%, Alvotech (ALVO) 70.5%, Dr Reddys Laboratories (RDY) 26.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMRX, ALVO and RDY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amneal Pharmaceuticals (AMRX) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.